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A recent paper published by Rodgers et al. describes a novel phase of stem cell quiescence, termed GAlert,
that serves to prime cells in response to injury-induced signals. These stem cells are located distal to the site
of injury and require mTORC1 activity to elicit the alert response.Adult stem cells possess the unique ability
to remain quiescent for long periods of
time. When triggered by tissue loss or
injury, these stem cells rapidly exit their
dormant state, known as G0, and become
activated to enter the G1 phase of the cell
cycle. Stem cell fate is determined in G1,
whereby differentiated daughter cells can
be generated or a return to quiescence
can be achieved (Cheung and Rando,
2013).The ability of stem cells to transition
from a quiescent, G0 state to an actively
cycling state is paramount to their re-
generative capacity, and an imbalance in
these two states can have pathologic
consequences (Rossi et al., 2012).
In a recent paper published in Nature,
Rodgers and colleagues describe the
existence of a novel, functional phase
of quiescence, termed ‘‘GAlert’’ (Rodgers
et al., 2014). They demonstrate that
upon induction of muscle injury in a single
limb of a mouse, muscle stem cells (satel-
lite cells) from the contralateral uninjured
limb muscle show a higher propensity to
enter the cell cycle when compared to
quiescent satellite cells without actually
proceeding to an activation stage (Rodg-
ers et al., 2014). Thus, they propose
that stem cell quiescence is actually
composed of two distinct phases, G0
and GAlert, and that stem cells can revers-
ibly transition to GAlert in response to injury
in order to be primed for activation and
entry into the cell cycle (Rodgers et al.,
2014).
Through a rigorous set of studies, the
authors characterize GAlert as an interme-
diate state between quiescence and acti-
vation. GAlert cells are slightly larger in size
and they are able to enter and completethe cell cycle faster than quiescent satel-
lite cells (Rodgers et al., 2014). Further-
more, GAlert cells have higher intracellular
ATP content and greater mitochondrial
activity when compared to quiescent
satellite cells (Rodgers et al., 2014)
(Figure 1). These parameters clearly
demonstrate that GAlert satellite cells fall
between the two traditional stem cell
states with a tendency to be more similar
to quiescent cells.
Until recently, the regulation of quies-
cence was poorly characterized and it
was presumed that quiescence was
simply a state of dormancy with little
cellular activity. The transcriptomes of
three distinct stem cell types, hemato-
poietic, muscle, and hair follicle stem
cells, in G0 compared to actively cycling
stem cells demonstrates downregulation
of genes involved in cell cycle progres-
sion including cyclins A2, B1, and E2
and mitochondrial biogenesis genes
such as cytochrome C. Upregulated
genes include those involved in stem
cell fate determination such as forkhead
box O3 (FOXO3) and enhancer of zeste
homology 1 (EZH1) (Cheung and Rando,
2013). In contrast, transcriptome ana-
lyses conducted by Rodgers et al.
demonstrate that genes specifically
involved in cell cycle regulation and
mitochondrial metabolism are signifi-
cantly upregulated in contralateral satel-
lite cells despite such cells maintaining
a state of quiescence and not entering
the active cell cycle (Rodgers et al.,
2014). This unique transcriptional profile
of contralateral satellite cells further sup-
ports their model describing a distinct
population of stem cells that exist in anCell Stemintermediate state between quiescence
and activation.
To address the functional significance
of the primed state of GAlert satellite cells,
Rodgers et al. demonstrated that GAlert
cells exhibit enhanced muscle regenera-
tive capacity in vivo after injury. Interest-
ingly, the GAlert response in satellite
cells was not specific to muscle injury
because a similar activation response
was observed after injury to bone and
skin. In addition, the GAlert response after
muscle injury is not restricted to satellite
cells, because fibro-adipogenic pro-
genitors and hematopoietic stem cells
also demonstrated a primed phenotype
accompanied by a more robust functional
response. These findings are of particular
interest because they suggest that the
primed stem cell status observed in satel-
lite cells may not be unique to muscle.
Future studies will need to address
whether other injured tissues elicit similar
responses.
Mammalian target of rapamycin (mTOR)
is a serine/threonine kinase that in-
teracts with several proteins to form one
of two large complexes: mTOR com-
plex 1 (mTORC1) or mTORC2. mTORC1
signaling predominantly regulates growth
and cell cycle progression and is sensitive
to diverse environmental stimuli including
stress and fluctuations in nutrient avail-
ability. Several of these stimuli transmit
their signals through tuberous sclerosis
proteins 1 and 2 (TSC1/2) that negatively
regulate mTORC1 activity (Laplante and
Sabatini, 2012). Increased mTORC1
signaling has been shown to activate
hematopoietic stem cell cycling (Gan
et al., 2008) and induces the differentiationCell 15, July 3, 2014 ª2014 Elsevier Inc. 7
Figure 1. Tissue Injury Elicits a Priming Response in Quiescent
Satellite Cells Located Distal to the Site of Injury
These quiescent satellite cells transition from a G0 to a GAlert phase that
manifests in increased cell size, mitochondrial activity, and ATP content and,
ultimately, a faster entry into the cell cycle.
Cell Stem Cell
Previewsof activated neural stem cells
(Hartman et al., 2013).
Because mTORC1 sig-
naling is a known regulator
of cell cycle progression in
diverse stem cell populations,
the authors confirmed active
mTORC1 signaling in GAlert
satellite cells and investigated
whether modulating this sig-
naling could regulate the
GAlert response. The authors
utilized the Pax7CreER driver
to ablate components of
mTORC1 signaling specif-
ically in satellite cells. Upon
TSC1 ablation that induces
increased mTORC1 activity,
they found quiescent satellite
cells in the GAlert state without
any contralateral injury. Con-
versely, satellite-cell-specific
ablation of Raptor, a member
of mTORC1, caused sup-
pressed mTORC1 signaling
in satellite cells accompanied
by a complete lack of the
GAlert phenotype in contralat-eral satellite cells after injury. Finally, the
authors targeted an upstream activator
of mTORC1 signaling, latent hepatocyte
growth factor (HGF), which normally re-
sides in the extracellular matrix and is
activated upon injury. Once active, HGF
signals via its receptor, cMet, to regulate
mTORC1 signaling. cMet knockout
blocked mTORC1 signaling and failed to
generate an alert response in contralateral
satellite cells after injury. Taken together,
these results demonstrate that mTORC1
activity is both necessary and sufficient
for quiescent satellite cells to enter the
alert phenotype. However, the mecha-
nism by which mTORC1 signaling is
activated in a population of stem cells
resident in muscle distal to the site of
injury remains unknown. One possibility8 Cell Stem Cell 15, July 3, 2014 ª2014 Elsevis the release or induction of a circulating
factor that serves as an activator of
mTORC1 at sites distal to the site of injury
(Figure 1); the priming of hematopoietic
stem cells after muscle injury would
support this hypothesis.
The current findings of a generalized
‘‘alerting response’’ to injury that is
tightly regulated by mTORC1 signaling
may also shed some light into previously
published data related to rapamycin (an
inhibitor of mTOR signaling) and aging.
In 2009, Harrison et al. (2009) reported
that rapamycin increased both mean
and maximum life span of mice, demon-
strating that all competing causes
of mortality (i.e., age-related diseases)
are delayed and suggesting that rapa-
mycin slows aging. In a subsequentier Inc.study, Neff et al. (2013)
demonstrated that while ra-
pamycin extended the over-
all life span of animals, it
did not ameliorate a number
of pathophysiological aging
phenotypes. Given that a
number of aging-related phe-
notypes are associated with
an overall decreased re-
generating capacity of certain
tissues, the current study by
Rodgers et al. (2014) may
explain this at least to some
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